论文部分内容阅读
Magnetic resonance (MR) imaging-histology co-registration techniques in combination with the use of MR contrast agents have been established for in vivo characterization of rodent models of primary and implanted liver tumors as a virtual biopsy(1-4).This has enabled disproving tumor selectivity of many "tumor-seeking" contrast agents including Gadophrin-2 or photosensitizers including porphyrin derivatives and hypericin used in cancer photodynamic therapy, but proving nonviable tissues (typically necrosis) as the real target of these compounds with many novel applications elicited(5-7).These agents should therefore be redefined as necrosis-avid compounds (NACs).Meanwhile, the in vivo tumoricidal events with antitubulin vascular targeting agents (VTAs) and radiofrequency ablation (RFA) have been noninvasively documented by this experimental platform(4, 8, 9).